A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer
HER2-positive Gastric Cancer
HER2-positive Non-Small Cell Lung Cancer
HER2-positive Colorectal Cancer
HER2-positive Tumors
HER2 Low Breast Cancer

Interventions

DRUG: XMT-2056

Sponsor

Mersana Therapeutics